US · FBIO
Fortress Biotech, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Bay Harbor Islands, FL 33154
- Website
- fortressbiotech.com
Price · as of 2024-12-31
$2.33
Market cap 106.15M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $17.44 | +648.5% |
| Intrinsic Value(DCF) | $0.62 | -73.39% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $49.32 | +2,016.87% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | $112.35 | ||||
| 2012 | $123.15 | ||||
| 2013 | $39.45 | ||||
| 2014 | $44.55 | ||||
| 2015 | $48.75 | ||||
| 2016 | $53.25 | $265.02 | $0.00 | $0.00 | $0.00 |
| 2017 | $74.25 | $111.89 | $0.00 | $0.00 | $0.00 |
| 2018 | $26.25 | $10.50 | $0.00 | $0.00 | $2,142.10 |
| 2019 | $30.00 | $12.00 | $0.00 | $0.00 | $0.00 |
| 2020 | $64.05 | $25.62 | $0.00 | $0.00 | $0.00 |
| 2021 | $20.40 | $8.16 | $0.04 | $0.00 | $0.00 |
| 2022 | $10.80 | $4.32 | $0.00 | $0.00 | $0.00 |
| 2023 | $2.10 | $0.84 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.54 | $17.44 | $0.00 | $0.00 | $49.32 |
AI valuation
Our deep-learning model estimates Fortress Biotech, Inc.'s (FBIO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $17.44
- Current price
- $2.33
- AI upside
- +648.5%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.62
-73.39% upside
Graham-Dodd
—
— upside
Graham Formula
$49.32
+2,016.87% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| FBIO | Fortress Biotech, Inc. | $2.33 | 106.15M | +648% | -73% | — | +2,017% | -0.26 | 1.41 | 0.55 | -0.49 | — | -3.51 | 63.80% | -191.38% | -79.75% | -533.80% | -308.14% | -77.53% | 3.34 | -11.12 | 1.27 | 0.95 | -0.18 | -6824.00% | -3176.00% | -3017.00% | -297.40% | -1.12 | -265.74% | 14.72% | -3.90% | 14.72% | -0.46 | -0.53 | 0.88 | -9.03 |
| ADAG | Adagene Inc. | $2.96 | 111.61M | +945% | -54% | — | +2,625% | -2.19 | 1.45 | 708.59 | -0.20 | -2.88 | 1.45 | -797.49% | -34835.42% | -32386.45% | -55.21% | 216.17% | -32.61% | 0.37 | -42.20 | 2.30 | 2.23 | 2.11 | 7593.00% | -9943.00% | 419.00% | -40.66% | -0.78 | 178.88% | 0.00% | 0.00% | 0.00% | -0.18 | -0.22 | 62.29 | -4.41 |
| CRVO | CervoMed Inc. | $3.99 | 36.92M | — | — | — | — | -1.10 | 0.46 | — | 1.16 | -0.75 | 0.46 | 0.00% | — | — | -69.95% | 26851.40% | -61.41% | 0.00 | — | 11.11 | 10.61 | 0.49 | 14634.00% | — | 12189.00% | -92.65% | -4.26 | 24352.48% | 0.00% | 0.00% | 6.76% | 1.16 | 1.28 | — | 0.16 |
| GANX | Gain Therapeutics, Inc. | $2.61 | 100.39M | +1,143% | — | — | — | -2.11 | 5.86 | — | -1.64 | — | 5.97 | 0.00% | — | — | -204.95% | 729.11% | -132.83% | 0.09 | — | 2.97 | 2.85 | 0.48 | -4795.00% | -10000.00% | 8.00% | -43.93% | -4.83 | 677.01% | 0.00% | 0.00% | 0.00% | -1.64 | -1.76 | — | -8.76 |
| IMUX | Immunic, Inc. | $1.02 | 100.66M | — | — | — | — | -16.98 | -247.31 | — | -16.85 | — | -247.31 | 0.00% | — | — | -1653.15% | 539.27% | -299.36% | -0.02 | — | 0.75 | 0.64 | 0.16 | -3800.00% | — | 110.00% | -5.21% | -2.80 | 449.10% | 0.00% | 0.00% | 0.00% | -15.84 | -19.02 | — | -17.75 |
| NTRB | Nutriband Inc. | $4.44 | 54.06M | +340% | -57% | — | — | -4.78 | 7.79 | 23.39 | -4.51 | -10.98 | 11.26 | 32.68% | -312.62% | -489.86% | -162.94% | -157.60% | -139.89% | 0.03 | -312.51 | 4.88 | 4.46 | 0.41 | 4348.00% | 262.00% | 3184.00% | -9.43% | -4.71 | -111.17% | 0.00% | 0.00% | 8.03% | -6.87 | -9.73 | 21.47 | 19.59 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| RLMD | Relmada Therapeutics, Inc… | $4.56 | 334.4M | — | — | — | — | -0.11 | 0.24 | — | 0.43 | — | 0.24 | 0.00% | — | — | -132.33% | 824.32% | -111.57% | 0.00 | — | 4.45 | 4.36 | 0.05 | -1921.00% | — | 19.00% | -597.84% | -5.03 | 508.56% | 0.00% | 0.00% | 0.00% | 0.43 | 0.70 | — | -24.19 |
| TCRX | TScan Therapeutics, Inc. | $1.06 | 60.15M | +2,649% | +18% | — | +7,924% | -1.74 | 0.92 | 78.74 | -0.24 | — | 0.92 | 100.00% | -4787.68% | -4527.66% | -65.08% | -271.01% | -39.64% | 0.40 | -36.91 | 8.14 | 8.07 | 0.68 | -1618.00% | -8662.00% | 7774.00% | -51.70% | -3.08 | -230.45% | 0.00% | 0.00% | 18.21% | -0.22 | -0.25 | 10.30 | -0.75 |
| XBIT | XBiotech Inc. | $2.26 | 68.9M | — | — | — | — | -2.57 | 0.54 | — | 1.76 | -4.62 | 0.54 | 0.00% | — | — | -19.21% | -219.51% | -18.10% | 0.06 | -52.63 | 11.56 | 11.49 | 4.51 | 5556.00% | — | 6905.00% | -32.59% | -2.05 | -166.91% | 0.00% | 0.00% | 0.00% | 1.49 | 1.97 | — | 3.15 |
About Fortress Biotech, Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
- CEO
- Lindsay Allan Rosenwald
- Employees
- 101
- Beta
- 1.42
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.62 ÷ $2.33) − 1 = -73.39% (DCF, example).